Action SCYX SCYNEXIS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues SCYNEXIS, Inc.

Actions

SCYX

US8112922005

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 14/05/2024 		Varia. 5j. Varia. 1 janv.
1,97 USD -3,43% Graphique intraday de SCYNEXIS, Inc. +6,78% -11,66%
08/05 SCYNEXIS, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024 CI
09/04 SCYNEXIS, Inc. présentera des données précliniques sur le fongicide de deuxième génération SCY-247 au 34e Congrès européen de microbiologie clinique et des maladies infectieuses CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Earnings Flash (SCYX) SCYNEXIS Reports Q1 Revenue $1.4M
Scynexis: Q1 Earnings Snapshot
SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update
SCYNEXIS, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
SCYNEXIS, Inc. to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases
SCYNEXIS, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update
SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference
SCYNEXIS, Inc. Presents Preclinical Data on Second Generation Fungerp SCY-247 Against Mucormycosis At the 11Th Advances Against Aspergillosis and Mucormycosis Conference
Final SCYX Investor Deadline: Bronstein, Gewirtz & Grossman LLC Announces that SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
SCYX DEADLINE NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important January 8 Deadline in Securities Class Action - SCYX
SCYX Bronstein, Gewirtz & Grossman LLC Announces that SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Pomerantz Law Firm Investigates Claims On Behalf of Investors of SCYNEXIS, Inc. - SCYX
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy
SCYX Investors Have Opportunity to Lead SCYNEXIS, Inc. Securities Fraud Lawsuit
SCYNEXIS Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options
SCYX Investors Have Opportunity to Lead SCYNEXIS, Inc. Securities Fraud Lawsuit
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action SCYX
  4. Actualités SCYNEXIS, Inc.
  5. Autres langues